Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration

Nature Chemical Biology

Volumn 9, Issue 9, 2013, Pages 586-594

  Tsvetkov, Andrey S ^a,b   Arrasate, Montserrat ^a,b,e   Barmada, Sami ^a   Ando, D Michael ^c   Sharma, Punita ^a,b   Shaby, Benjamin A ^d   Finkbeiner, Steven ^a,b,c  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b Taube Koret Center for Huntington's Disease Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Duke University   (United States)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; AUTOPHAGY; BRAIN CELL; CELL LABELING; CELL SPECIFICITY; CELL SURVIVAL; CLEARANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; HUNTINGTON CHOREA; LONGEVITY; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OPTICAL PULSE LABELING; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; RAT;

HALF-LIFE; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURONS; PEPTIDES; PROTEOLYSIS; PROTEOSTASIS DEFICIENCIES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84883204078     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1308     Document Type: Article

References (36)

1. Han, I., You, Y., Kordower, J.H., Brady, S.T. & Morfini, G.A. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 113, 1073-1091 (2010).
2. Taylor, J.P., Hardy, J. & Fischbeck, K.H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
3. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
4. Miller, J. et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 7, 925-934 (2011).
5. Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R. & Morimoto, R.I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471-1474 (2006).
6. Mitra, S., Tsvetkov, A.S. & Finkbeiner, S. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in Huntington disease. J. Biol. Chem. 284, 4398-4403 (2009).
7. Tsvetkov, A.S. et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc. Natl. Acad. Sci. USA 107, 16982-16987 (2010).
8. Takahashi, M. & Ono, Y. Pulse-chase analysis of protein kinase C. Methods Mol. Biol. 233, 163-170 (2003).
9. Gurskaya, N.G. et al. Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. Nat. Biotechnol. 24, 461-465 (2006).
10. Arrasate, M. & Finkbeiner, S. Automated microscope system for determining factors that predict neuronal fate. Proc. Natl. Acad. Sci. USA 102, 3840-3845 (2005).
11. Leutenegger, A. et al. It's cheap to be colorful. Anthozoans show a slow turnover of GFP-like proteins. FEBS J. 274, 2496-2505 (2007).
12. Dantuma, N.P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M.G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome- dependent proteolysis in living cells. Nat. Biotechnol. 18, 538-543 (2000).
13. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
14. DiFiglia, M. Clinical Genetics, II. Huntington's disease: from the gene to pathophysiology. Am. J. Psychiatry 154, 1046 (1997).
15. Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. USA 110, 2366-2370 (2013).
16. Wellington, C.L. & Hayden, M.R. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet. 57, 1-10 (2000).
17. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
18. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
19. Persichetti, F. et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis. 3, 183-190 (1996).
20. Dyer, R.B. & McMurray, C.T. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat. Genet. 29, 270-278 (2001).
21. Kaytor, M.D., Wilkinson, K.D. & Warren, S.T. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity. J. Neurochem. 89, 962-973 (2004).
22. Roscic, A., Baldo, B., Crochemore, C., Marcellin, D. & Paganetti, P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 119, 398-407 (2011).
23. Wu, J.C. et al. The regulation of N-terminal Huntingtin (Htt552) accumulation by Beclin1. Acta Pharmacol. Sin. 33, 743-751 (2012).
24. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA 96, 11404-11409 (1999).
25. Kopito, R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530 (2000).
26. Hartl, F.U. & Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 16, 574-581 (2009).
27. Snell, R.G. et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4, 393-397 (1993).
28. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66 (1998).
29. Matsumoto, G., Kim, S. & Morimoto, R.I. Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells. J. Biol. Chem. 281, 4477-4485 (2006).
30. Lin, C.H. et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10, 137-144 (2001).
31. Colby, D.W., Cassady, J.P., Lin, G.C., Ingram, V.M. & Wittrup, K.D. Stochastic kinetics of intracellular huntingtin aggregate formation. Nat. Chem. Biol. 2, 319-323 (2006).
32. Slow, E.J. et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 102, 11402-11407 (2005).
33. Tsakiri, E.N. et al. Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging Cell http://dx.doi.org/10.1111/acel.12111 (2013).
34. Riley, B.E. et al. Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J. Cell Biol. 191, 537-552 (2010).
35. Zhang, Q.C. et al. A compact β model of huntingtin toxicity. J. Biol. Chem. 286, 8188-8196 (2011).
36. Bilimoria, P.M. & Bonni, A. Cultures of cerebellar granule neurons. Cold Spring Harb. Protoc. http://dx.doi.org/10.1101/pdb.prot5107 (2008).